1 / 56

Gerard Ryan T. Mercadal , MD THE MEDICAL CITY

ONE YEAR OUTCOME AFTER MEDICAL THERAPY, PERCUTANEOUS CORONARY INTERVENTION (PCI), AND CORONARY ARTERY BYPASS GRAFT (CABG) IN PATIENTS WITH 3-VESSEL AND/OR LEFT MAIN CORONARY ARTERY DISEASE. PHILIPPINE HEART ASSOCIATION May 24, 2012. Gerard Ryan T. Mercadal , MD THE MEDICAL CITY.

karena
Download Presentation

Gerard Ryan T. Mercadal , MD THE MEDICAL CITY

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ONE YEAR OUTCOME AFTER MEDICAL THERAPY, PERCUTANEOUS CORONARY INTERVENTION (PCI), AND CORONARY ARTERY BYPASS GRAFT (CABG) IN PATIENTS WITH 3-VESSEL AND/OR LEFT MAIN CORONARY ARTERY DISEASE PHILIPPINE HEART ASSOCIATION May 24, 2012 Gerard Ryan T. Mercadal, MD THE MEDICAL CITY

  2. MEDICAL AND CATHETERIZATION RECORDS

  3. 4. Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/ AHA Guideline for coronary artery bypass graft surgery: Executive summary: A report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists and Society of Thoracic Surgeons. Journal of the American College of Cardiology 2011; 58 (24):2584-2614

  4. 4. Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/ AHA Guideline for coronary artery bypass graft surgery: Executive summary: A report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists and Society of Thoracic Surgeons. Journal of the American College of Cardiology 2011; 58 (24):2584-2614

  5. 6. Kim LJ, King III SB, Kent K, et al. Factors Related to the Selection of Surgical Versus Percutaneous Revascularization in Diabetic Patients With Multivessel Coronary Artery Disease in the BARI 2D (Bypass Angioplasty RevascularizationInvestigation in Type 2 Diabetes) Trial. JACC: Cardiovascular Interventions 2009; 2(5): 384-392

  6. 7. Hoffman SN, TenBrookJr JA, Wolf MP, et al. A meta-analysis of randomized controlled trials comparing coronary artery bypass graft with percutaneous transluminal coronary angioplasty: One- to eight-year outcomes. Journal of the American College of Cardiology 2003; 41(8):1293-1304

  7. 8. Daemen J, Boersma E, Flather M, et al. Long-term safety and efficacy of percutaneous coronary intervention with stenting and coronary artery bypass surgery for multivessel coronary artery disease: A meta-analysis with 5-year patient-level data from the ARTS, ERACI-II, MASS-II, and SoS Trials. Circulation 2008; 118: 1146-54

  8. 9. Boeden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary artery disease. N Engl J Med 2007; 356: 1503-1516 10. Pell JP, Walsh D, Norrie J, et al. Outcomes following coronary artery bypass grafting and percutaneous transluminal coronary angioplasty in the stent era: a prospective study of all 9890 consecutive patients operated on in Scotland over a two year period. Heart 2001; 85: 662-666 11. Park DW, Yun SC, Lee SW, et al. Long term mortality after percutaneous coronary intervention with drug-eluting stent implantation versus coronary artery bypass surgery for the treatment of multivessel coronary artery disease. Circulation 2008; 117: 2079-2086 12. Rodriguez AE, Maree AO, Mieres J, et al. Late loss of early benefit from drug-eluting stents when compared with bare-metal stents and coronary artery bypass surgery: 3 years follow-up of the ERACI III registry. European Heart Journal 2007; 28: 2118-2125

  9. 9. Boeden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary artery disease. N Engl J Med 2007; 356: 1503-1516

  10. 14. Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N ENGL J MED 2009; 360: 961-72

  11. 14. SerruysPW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N ENGL J MED 2009; 360: 961-72

  12. 15. Serruys PW, Ong ATL, van Herwerden LA, et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: The final analysis of the Arterial Revascularization Therapies Study (ARTS) Randomized Trial. Journal of the American College of Cardiology 2005; 46:575-581 16. SerruysPW, Onuma Y, Garg S, et al. Five-year clinical outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the Sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions. Journal of the American College of Cardiology 2010; 55(11):1093-1101

More Related